# Syndax Announces Participation in Upcoming Investor Conferences
Canonical URL: https://biopharmsignal.com/news/SNDX/syndax-announces-participation-in-upcoming-investor-conferences
Ticker: SNDX
Company: Syndax Pharmaceuticals
Source: Syndax Pharmaceuticals
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.syndax.com
## Summary

NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate

## Article Body
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate
## Recent Company News
- 2026-06-25 13:46 EST — [Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026](https://biopharmsignal.com/news/SNDX/syndax-showcases-revuforjr-revumenib-clinical-activity-in-multiple-acute-leukemia-subtypes-and-settings-at-eha-2026) — Source: Syndax Pharmaceuticals
- 2026-06-25 13:46 EST — [Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology](https://biopharmsignal.com/news/SNDX/syndax-announces-publication-of-save-data-on-revuforjr-revumenib-in-combination-with-decitabine-cedazuridine-and-venetoclax-in-relapsed-refractory-npm1m-kmt2ar-and-nup98r-aml-in-the-journal-of-clinical-oncology) — Source: Syndax Pharmaceuticals
- 2026-06-25 13:46 EST — [Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes](https://biopharmsignal.com/news/SNDX/syndax-announces-private-placement-of-250-0-million-of-convertible-senior-notes) — Source: Syndax Pharmaceuticals
- 2026-06-25 13:46 EST — [Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data](https://biopharmsignal.com/news/SNDX/syndax-highlights-revuforjr-revumenib-data-presented-at-asco-2026-including-an-oral-presentation-of-post-transplant-data) — Source: Syndax Pharmaceuticals
- 2026-06-25 13:46 EST — [Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026](https://biopharmsignal.com/news/SNDX/syndax-to-host-randd-day-highlighting-its-late-stage-programs-and-early-stage-assets-on-july-14-2026) — Source: Syndax Pharmaceuticals
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)